Best option for emmetropia, intermediate and near vision: 3 years clinical results and patient satisfaction with toric trifocal IOL

Session Details

Session Title: Pseudophakic IOLs: Toric

Session Date/Time: Tuesday 10/10/2017 | 08:30-10:30

Paper Time: 10:04

Venue: Room 4.4

First Author: : M.Piovella ITALY

Co Author(s): :    B. Kusa                    

Abstract Details

Purpose:

To evaluate trifocal toric IOL in cataract surgery to manage astigmatism, achieve postoperative emmetropia with optimal uncorrected intermediate and near vision.

Setting:

C.M.A. Centro Microchirurgia Ambulatoriale Monza – Italy

Methods:

Eyes with cataract and corneal astigmatism (1.46 D ± 0.54 D) received AT LISA tri toric 939MP implantation. Toric IOL was implanted when corneal astigmatism was of 0.75 diopters or more. IOL calculation was performed with online calculator, considering surgeon SIA. Accurate intraoperative IOL alignment was performed using digital device. Outcomes measurements were: subjective refraction, topographic corneal astigmatism, visual acuity, contrast sensitivity.

Results:

Study included 94 eyes from 57 patients (mean age 66.48 years ± 12.50). Preoperatively, mean BCVA and SE were 20/31 ± 14.63 and -0.65 D ± 3.28. Patients showed mean corneal cylinder and mean refractive cylinder of 1.46 D ± 0.54 D and 0.93 D ± 0.91 D , respectively. Three years postoperatively, mean monocular distance UCVA and BCVA were 20/24.24 ± 0.17 and 20/20 ± 0.14. Intermediate monocular UCVA was 20/35 ± 0.29. Near monocular UCVA was 20/28.10. Mean residual refractive cylinder was 0.33 ± 0.33. Photopic contrast sensitivity for lower spatial frequencies was within the normal range.

Conclusions:

Toric trifocal IOL is an advanced generation of multifocal IOL indicated for bilateral implantation. Clinical outcomes highlight this as an effective multifocal design for the correction of corneal astigmatism, with pursue of emmetropia and good uncorrected intermediate and near vision. Toric IOL correction is mandatory for a corneal astigmatism of 0.75 diopters or more.

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented